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Severe TB has recently been described in association with
TNF-α blocker therapy. Furthermore conventional tuber-
culin skin test (TST) may give false-negative results in
patients receiving biological therapy. New in vitro test,
based on the detection of IFN-γ release by T-cell stimu-
lated with M. tuberculosis specific antigens (IGRA), are
available for LTBI diagnosis, promising to be more sensi-
tive and specific than TST. Nevertheless no sufficient evi-
dence on IGRA performance are available in children. The
performance of two commercially available IGRAs, ELIS-
POT-TB (TS-TB) and Quantiferon-TB gold in-Tube (QFT-
GIT), were evaluated in comparison with TST in children
with rheumatic diseases. In children with positive result
clinical and radiological evidence of TB was sought. Nine-
teen children with JIA were enrolled since November
2006 (median age 13.5 years; range 2–18). Seventeen
children were on long term etanercept therapy plus meth-
otrexate (15 mg/m2/week), 1 on infliximab and 1
received adalimubab plus prednisone (0,2 mg/Kg/die).
Five children (26%) showed positive TS-TB, QFT-GIT and
TST were negative in all children. Both QFT-GIT and TS-TB
showed a high percentage of indeterminate results (21%
and 16% respectively). None of the 5 patients positive at
TS-TB developed active disease, as judged by clinical and
radiological findings, at least in a median follow-up
period of 16 months (range 9–17 months). Our data sug-
gest that high rate of positive results by TS-TB is expression
of non-specific immune reactivity in rheumatic children.
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